Yerevan
Tbilisi
Moscow
Paris
Los Angeles
Beijing
English
Հայերեն Русский
Main Timeline Video Share
May the Holiday Warm Hearts: Idram and IDBank Support the Children of Heroes Beneficiaries of the "By Your Side" program at IDBank AraratBank Named Large CSR Company of the Year Idram Joins the Fight Against Food Insecurity Ucom’s Renovated Sales and Service Center in Yerevan Mall Reopens 1% idcoin instead of New Year’s suffering: practical tips Idram Junior Donated Books to Schools Big Christmas Market with Idram, IDBank and idplus Ucom Supports Wildlife Monitoring in Ararat Region IDBank, Idram, and idplus at the Big Christmas Market Converse Bank Deputy CEO and CFO, Grant Akopian, Elected to BACEE Board Ucom and SunChild NGO Install a Solar Plant in Alaverdi Kindergarten
Timeline
AraratBank Participates in “Women’s Empowerment Principles in Armenia” Conference Unibank’s Perpetual Bonds Were Acquired in Nearly One Day Acba bank and France’s Proparco to continue strengthening their long-term strategic partnershipTeam Holding Announces the Launch of Bond Placement. Underwriter - Freedom Broker Armenia Unibank Issues the First in Armenia Perpetual Bonds Team Holding Announces the Launch of Bond Placement. Underwriter - Freedom Broker Armenia AraratBank Joins Armenia's New Greening Initiative: 100 Hectares of New Forest within Three YearsApply for a Unibank salary card and get a chance to win 1 000 000 AMDEuromoney Names Ameriabank Armenia’s Best Bank for Real Estate for the Second Year in a Row S&P Global Ratings has assigned IDBank CJSC a long-term rating of “BB-” and a short-term rating of “B” with a “stable” prospectAn unprecedented Evening for the Armenian Fashion and Hospitality Industry: World-Renowned Dress Designer Jacob Meyer Presents His Masterpieces at the ONE&ONLY Antigravity Theatre in The Dvin HotelA Brand-New Section on Idram&IDBankSeveral real and profitable offers ahead of Black Friday: IDBank and IdramAraratBank Joins Social Impact Award 2025 Summit in LjubljanaIDBank issued the 1st tranche of bonds of 2026Ucom Supports the Development of Space Engineering in Armenia Prioritizing Information Security: IDBank and Idram Support APOCALYPSE CTF 2025IDBank's Representative, Innesa Amirbekyan Appointed Co-Chair of the ICC Banking Commission Task Force on GuaranteesUcom General Director Ralph Yirikian Awards Certificates to Participants of Cybersecurity Training Course Acba and Proparco mark one year of partnership, strengthening rural financing and Armenias’s economic resilience
All Timeline »
Life
echo '
';

Multiple sclerosis drug shows promising efficacy

The multiple sclerosis drug is showing promising efficacy in fighting relapses and reducing fatigue.

Back in March 2001, the US Food and Drug Administration approved a drug called ponosimod for use in adult patients with various types of multiple sclerosis. Only now there are research data that show that some drug reduces the number of relapses of the disease and can reduce fatigue - one of the characteristic symptoms of multiple sclerosis.

The respected scientific journal JAMA Neurology has found that ponesimod is more effective in fighting fatigue in multiple sclerosis than another commonly used drug called teriflunomide. It is superior to teriflunomide in reducing relapse rates and reducing the risk of new or existing lesions of myelin found on magnetic resonance imaging.

As reported by everydayhealth.com, ponesimod is used for various types of multiple sclerosis, including the most common relapsing remitting disease and active secondary progressive, which is the most severe. It is not accompanied by remissions and steadily leads to the disability of patients. It is people with this form of multiple sclerosis who show the appearance of new lesions of the myelin layer on MRI scans. Ponesimod must be taken once a day, treatment begins with a period of 14 days, then the doses are increased.